ARG54669
anti-LC3C antibody
anti-LC3C antibody for ELISA,ICC/IF,Immunohistochemistry,Western blot and Human
Cancer antibody; Cell Biology and Cellular Response antibody; Cell Death antibody; Metabolism antibody; Signaling Transduction antibody
Overview
| Product Description | Rabbit Polyclonal antibody recognizes LC3C |
|---|---|
| Tested Reactivity | Hu |
| Tested Application | ELISA, ICC/IF, IHC, WB |
| Specificity | MAP1LC3C antibody is human, mouse and rat reactive. Multiple isoforms MAP1LC3C are known to exist. MAP1LC3C antibody is predicted to not cross-react with MAP1LC3A or MAP1LC3B. |
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Target Name | LC3C |
| Immunogen | Synthetic peptide (18 aa) within the last 50 aa of Human MAP1LC3C. |
| Conjugation | Un-conjugated |
| Alternate Names | Microtubule-associated proteins 1A/1B light chain 3C; MAP1A/MAP1B light chain 3 C; ATG8J; Microtubule-associated protein 1 light chain 3 gamma; MAP1 light chain 3-like protein 3; MAP1A/MAP1B LC3 C; Autophagy-related protein LC3 C; LC3C; Autophagy-related ubiquitin-like modifier LC3 C |
Application Instructions
| Application Suggestion |
|
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Application Note | * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. | ||||||||||
| Positive Control | Human Brain Tissue Lysate | ||||||||||
| Observed Size | 16 kDa |
Properties
| Form | Liquid |
|---|---|
| Purification | Affinity purification with immunogen. |
| Buffer | PBS and 0.02% Sodium azide |
| Preservative | 0.02% Sodium azide |
| Concentration | 1 mg/ml |
| Storage Instruction | For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C or below. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. |
| Note | For laboratory research only, not for drug, diagnostic or other use. |
Bioinformation
| Database Links |
Swiss-port # Q9BXW4 Human Microtubule-associated proteins 1A/1B light chain 3C |
|---|---|
| Gene Symbol | MAP1LC3C |
| Gene Full Name | microtubule-associated protein 1 light chain 3 gamma |
| Background | Microtubule-associated proteins (MAPs) regulate microtubule stability and play critical roles in neuronal development and plasticity (1). MAP1LC3C belongs to the MAP1 LC3 family of proteins that form mature complexes with MAP1A and MAP1B which are thought to be important in the formation and development of axons and dendrites (2). MAP1LC3C is one of three isoforms of MAP1LC3, the mammalian homolog of yeast ATG8, an essential autophagy protein. These isoforms exhibit distinct expression patterns and MAP1LC3C, like MAP1LC3A but not MAP1LC3B, is post-translationally modified, suggesting the three isoforms may have different physiological functions (3). | |
| Research Area | Cancer antibody; Cell Biology and Cellular Response antibody; Cell Death antibody; Metabolism antibody; Signaling Transduction antibody |
| Calculated MW | 17 kDa |
| PTM | The precursor molecule is cleaved by ATG4B to form the cytosolic form, LC3-I. This is activated by APG7L/ATG7, transferred to ATG3 and conjugated to phospholipid to form the membrane-bound form, LC3-II (PubMed:15187094). The Legionella effector RavZ is a deconjugating enzyme that produces an ATG8 product that would be resistant to reconjugation by the host machinery due to the cleavage of the reactive C-terminal glycine. |
Images (3) Click the Picture to Zoom In
-
ARG54669 anti-MAP1LC3C antibody ICC/IF image
Immunofluorescence: human brain tissue stained with ARG54669 anti-MAP1LC3C antibody at 20 μg/ml.
-
ARG54669 anti-MAP1LC3C antibody IHC image
Immunohistochemistry: human brain tissue stained with ARG54669 anti-MAP1LC3C antibody at 5 μg/ml.
-
ARG54669 anti-MAP1LC3C antibody WB image
Western blot: human brain tissue lysate stained with ARG54669 anti-MAP1LC3C antibody at 1 μg/ml in (A) the absence and (B) the presence of blocking peptide.
